By Agnes Shanley, Editor in ChiefOnce a company introduces multivariate (MV) sensors and chemometrics and understand its processes, should it replace those MV sensors with simpler and cheaper sensors or timers? This was only one of the many relevant questions raised and discussed at the IFPAC summit meetings in San Juan on September 8 and 9. It also provides some insight into the tone of the event, which dispensed with the self-congratulations and PAT primers and went straight to the heart of the implementation challenges facing todays pharmaceutical PAT teams.
Photo of Old San Juan courtesy of www.solboricua.com/sanjuan.htm
The Summit, which brought together diverse lecturers from widely different backgrounds, was a group effort. It was organized by the International Foundation of Process Analytical Chemistry (IFPAC), the Puerto Rico Research Consortium of Pharmaceuticals and Academia (INDUNIV), the PAT systems integrator, IBS Caribe Inc., and Dr. R. Romañach from the University of Puerto Rico-Mayaguez.Its program was carefully balanced to reflect both regulatory and corporate viewpoints. For example, a review from FDA on how its PAT team approached the task of reviewing Sanofi-Aventis PAT installation in Kansas City was followed by Sanofi-Aventis perspectives on the same project. Subsequent presentations covered a wide range of business strategies and technological PAT tools needed for a successful implementation.Focus was also important, and aided by open discussion of practical issues, involving manufacturing specialists, researchers, vendors and outsiders experienced in applying PAT concepts outside of the pharma industry, who brought fresh perspectives. Although an introductory lecture was included for those new to PAT, most of the discussion was devoted to discussing the real-life challenges and problems that manufacturing professionals are encountering in their PAT programs.For those of you who could not attend, this brief summary should provide some insights.The program in a nutshellCarlos Tollinche, PhD., Director of INDUNIVs Scientific Affairs Board, kicked off the program, providing an overview of the pharma and biopharma industries, both globally and in Puerto Rico.Rebeca Rodriguez, FDAs National Investigator, discussed FDAs approach to a PAT implementation inspection when she was part of the PATRIOT team reviewing the Sanofi-Aventis comparability protocol in Kansas City. She emphasized the Agencys risk-based approach to inspections and its search for evidence of process knowledge and understanding. A critical part of implementing PAT, Rodriguez said, is taking a holistic view and understanding the ultimate goal, instead of focusing only on specific issues, such as designing, analyzing or controlling.Following her presentation, Chan Cai, Ph.D., from Sanofi-Aventis, presented his view from the other side. His team implemented PAT throughout an entire production cycle, to better understand how the variability of the in-process measurements affected the downstream processes and final product quality. The measurements included:
The Summit, which brought together diverse lecturers from widely different backgrounds, was a group effort. It was organized by the International Foundation of Process Analytical Chemistry (IFPAC), the Puerto Rico Research Consortium of Pharmaceuticals and Academia (INDUNIV), the PAT systems integrator, IBS Caribe Inc., and Dr. R. Romañach from the University of Puerto Rico-Mayaguez.Its program was carefully balanced to reflect both regulatory and corporate viewpoints. For example, a review from FDA on how its PAT team approached the task of reviewing Sanofi-Aventis PAT installation in Kansas City was followed by Sanofi-Aventis perspectives on the same project. Subsequent presentations covered a wide range of business strategies and technological PAT tools needed for a successful implementation.Focus was also important, and aided by open discussion of practical issues, involving manufacturing specialists, researchers, vendors and outsiders experienced in applying PAT concepts outside of the pharma industry, who brought fresh perspectives. Although an introductory lecture was included for those new to PAT, most of the discussion was devoted to discussing the real-life challenges and problems that manufacturing professionals are encountering in their PAT programs.For those of you who could not attend, this brief summary should provide some insights.The program in a nutshellCarlos Tollinche, PhD., Director of INDUNIVs Scientific Affairs Board, kicked off the program, providing an overview of the pharma and biopharma industries, both globally and in Puerto Rico.Rebeca Rodriguez, FDAs National Investigator, discussed FDAs approach to a PAT implementation inspection when she was part of the PATRIOT team reviewing the Sanofi-Aventis comparability protocol in Kansas City. She emphasized the Agencys risk-based approach to inspections and its search for evidence of process knowledge and understanding. A critical part of implementing PAT, Rodriguez said, is taking a holistic view and understanding the ultimate goal, instead of focusing only on specific issues, such as designing, analyzing or controlling.Following her presentation, Chan Cai, Ph.D., from Sanofi-Aventis, presented his view from the other side. His team implemented PAT throughout an entire production cycle, to better understand how the variability of the in-process measurements affected the downstream processes and final product quality. The measurements included:
- raw material attributes such as real-time ID, moisture content, and particle size;
- real-time granulation moisture level during drying;
- real-time material concentration profile during blending;
- content uniformity, moisture content, and hardness profile during tablet compression.
- control the drying and blending time automatically;
- predict final tablet dissolution performance;
- feed forward the optimal settings for the compression equipment to reduce startup product loss and improve dissolution.
Latest from Automation & Control
Latest from Automation & Control